Neuroregeneration in Parkinson's Disease : From Proteins to Small Molecules. / Sidorova, Yulia A.; Volcho, Konstantin P.; Salakhutdinov, Nariman F.
In: Current Neuropharmacology, Vol. 17, No. 3, 01.01.2019, p. 268-287.Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - Neuroregeneration in Parkinson's Disease
T2 - From Proteins to Small Molecules
AU - Sidorova, Yulia A.
AU - Volcho, Konstantin P.
AU - Salakhutdinov, Nariman F.
N1 - Publisher Copyright: © 2019 Bentham Science Publishers.
PY - 2019/1/1
Y1 - 2019/1/1
N2 - BACKGROUND: Parkinson's disease (PD) is the second most common neurodegenerative disorder worldwide, the lifetime risk of developing this disease is 1.5%. Motor diagnostic symptoms of PD are caused by degeneration of nigrostriatal dopamine neurons. There is no cure for PD and current therapy is limited to supportive care that partially alleviates disease signs and symptoms. As diagnostic symptoms of PD result from progressive degeneration of dopamine neurons, drugs restoring these neurons may significantly improve treatment of PD. METHOD: A literature search was performed using the PubMed, Web of Science and Scopus databases to discuss the progress achieved in the development of neuroregenerative agents for PD. Papers published before early 2018 were taken into account. RESULTS: Here, we review several groups of potential agents capable of protecting and restoring dopamine neurons in cultures or animal models of PD including neurotrophic factors and small molecular weight compounds. CONCLUSION: Despite the promising results of in vitro and in vivo experiments, none of the found agents have yet shown conclusive neurorestorative properties in PD patients. Meanwhile, a few promising biologicals and small molecules have been identified. Their further clinical development can eventually give rise to disease-modifying drugs for PD. Thus, intensive research in the field is justified.
AB - BACKGROUND: Parkinson's disease (PD) is the second most common neurodegenerative disorder worldwide, the lifetime risk of developing this disease is 1.5%. Motor diagnostic symptoms of PD are caused by degeneration of nigrostriatal dopamine neurons. There is no cure for PD and current therapy is limited to supportive care that partially alleviates disease signs and symptoms. As diagnostic symptoms of PD result from progressive degeneration of dopamine neurons, drugs restoring these neurons may significantly improve treatment of PD. METHOD: A literature search was performed using the PubMed, Web of Science and Scopus databases to discuss the progress achieved in the development of neuroregenerative agents for PD. Papers published before early 2018 were taken into account. RESULTS: Here, we review several groups of potential agents capable of protecting and restoring dopamine neurons in cultures or animal models of PD including neurotrophic factors and small molecular weight compounds. CONCLUSION: Despite the promising results of in vitro and in vivo experiments, none of the found agents have yet shown conclusive neurorestorative properties in PD patients. Meanwhile, a few promising biologicals and small molecules have been identified. Their further clinical development can eventually give rise to disease-modifying drugs for PD. Thus, intensive research in the field is justified.
KW - BDNF
KW - BDNF mimetics
KW - dopamine neurons
KW - GDNF
KW - GDNF mimetics
KW - neuroprotection
KW - Neurorestoration
KW - neurotrophic factors.
KW - Parkinson's disease
KW - RET agonists
KW - Trk agonists
KW - MITOCHONDRIAL BIOGENESIS
KW - ADRENAL-MEDULLARY AUTOGRAFTS
KW - SUBSTANTIA-NIGRA
KW - MIDBRAIN DOPAMINERGIC-NEURONS
KW - RAT MODEL
KW - NERVE GROWTH-FACTOR
KW - NEUROTROPHIC FACTOR GDNF
KW - neurotrophic factors
KW - MOUSE MODEL
KW - DOUBLE-BLIND
KW - NEURAL PRECURSOR CELLS
KW - Dopamine neurons
KW - Neurotrophic factors
KW - Neurorestoration, neuroprotection
KW - Parkinson’s disease
UR - http://www.scopus.com/inward/record.url?scp=85062087375&partnerID=8YFLogxK
U2 - 10.2174/1570159X16666180905094123
DO - 10.2174/1570159X16666180905094123
M3 - Review article
C2 - 30182859
AN - SCOPUS:85062087375
VL - 17
SP - 268
EP - 287
JO - Current Neuropharmacology
JF - Current Neuropharmacology
SN - 1570-159X
IS - 3
ER -
ID: 18617302